A Phase III, Prospective, Randomised, Open Label Study to Compare the Efficacy and Safety of Lanreotide Autogel 60, 90 or 120 mg With Lanreotide 40 mg PR in Subjects With Active Acromegaly
Phase of Trial: Phase III
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Lanreotide (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms LANTERN
- Sponsors Ipsen
- 10 Jun 2017 Biomarkers information updated
- 27 Feb 2017 Status changed from active, no longer recruiting to completed.
- 30 Jun 2016 Planned End Date changed from 1 Apr 2017 to 1 Jan 2017.